Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Utidelone UTD1 in metastatic castration-resistant prostate cancer after standard treatment failure
ChiCTR2200058568Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: PSA remission rate. Started Apr 2022; status: recruiting.
02
Drugs
utidelone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2200058568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058568.